Charles Schwab Investment Management Inc. lifted its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 5.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 426,434 shares of the company's stock after purchasing an additional 23,869 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.82% of PROCEPT BioRobotics worth $34,336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also modified their holdings of PRCT. Raleigh Capital Management Inc. purchased a new stake in PROCEPT BioRobotics during the fourth quarter valued at approximately $32,000. IFP Advisors Inc purchased a new position in PROCEPT BioRobotics during the 4th quarter worth $58,000. Arcadia Investment Management Corp MI acquired a new position in PROCEPT BioRobotics during the 4th quarter valued at approximately $64,000. Wilmington Savings Fund Society FSB purchased a new position in PROCEPT BioRobotics during the 3rd quarter worth approximately $64,000. Finally, Canton Hathaway LLC acquired a new stake in PROCEPT BioRobotics during the third quarter worth about $66,000. Institutional investors own 89.46% of the company's stock.
PROCEPT BioRobotics Stock Up 2.4 %
Shares of PROCEPT BioRobotics stock traded up $1.41 during trading on Monday, reaching $59.03. The stock had a trading volume of 692,677 shares, compared to its average volume of 720,542. The stock has a fifty day moving average price of $70.07 and a two-hundred day moving average price of $79.05. PROCEPT BioRobotics Co. has a 52 week low of $45.56 and a 52 week high of $103.81. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $3.24 billion, a price-to-earnings ratio of -30.27 and a beta of 1.05.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). The company had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. Sell-side analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts recently commented on PRCT shares. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Morgan Stanley cut their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Finally, Truist Financial reiterated a "buy" rating and issued a $90.00 price objective (down from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $94.29.
Read Our Latest Stock Report on PRCT
About PROCEPT BioRobotics
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Further Reading
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
